Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.51 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.50 |
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6608253 | 0.84 | OPRM1 (0.55) | OPRM1SIGMAR1KCNA3MC4ROPRL1 | |
| SCHEMBL7632302 | 0.82 | OPRM1 (0.56) | OPRM1SIGMAR1KCNA3MC4ROPRL1 | |
| SCHEMBL14902471 | 0.79 | OPRM1 (0.60) | OPRM1SIGMAR1OPRL1CCR3CYP3A4 | |
| SCHEMBL16915778 | 0.78 | OPRM1 (0.58) | OPRM1SIGMAR1MC4ROPRL1CCR3 | |
| SCHEMBL7625247 | 0.78 | SIGMAR1 (0.56) | SIGMAR1MC4ROPRL1CCR3CYP3A4 | |
| SCHEMBL7620722 | 0.77 | SIGMAR1 (0.51) | SIGMAR1MC4RCCR3LMNAPOLB | |
| SCHEMBL7623444 | 0.77 | SIGMAR1 (0.55) | SIGMAR1MC4ROPRL1CCR3CYP3A4 | |
| SCHEMBL14387152 | 0.76 | OPRM1 (0.56) | OPRM1SIGMAR1OPRL1CYP3A4HSD17B10 | |
| SCHEMBL4630573 | 0.76 | OPRM1 (0.63) | OPRM1SIGMAR1MC4ROPRL1CCR3 | |
| SCHEMBL5199646 | 0.75 | OPRM1 (0.55) | OPRM1SIGMAR1KCNA3MC4ROPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1106614-B1 | 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER (US) | 2004-01-07 | — | — | EP | disclosed |
| US-6444677-B2 | TREATMENT OF INFLAMMATION, CARDIOVASCULAR DISEASE, PAIN, ETC. | PFIZER INC. | 2002-09-03 | — | — | US | disclosed |
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | IKEDA TAKAFUMI (JP) | 2001-11-29 | — | — | US | disclosed |
| EP-1106614-A1 | 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 2001-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, CNR2 | OPRM1 42/4885SIGMAR1 127/4885KCNA3 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.